

# 个人简介

## 个人信息

姓名: 韩涛 出生年月: 19860401  
民族: 汉族 所在学系: 生化与分子生物学系  
职称: 校聘教授 行政职务: 无  
电话: 15737300401 最后学历学位: 研究生, 博士  
邮箱: doubleyingtao@gmail.com 毕业院校: 武汉大学



## 从事专业及研究方向

- Cdh1/Cdc20 泛素化连接酶与肿瘤发生的分子机制
- 肿瘤的基因靶向治疗
- 病毒感染, 复制与免疫

## 教育背景及工作经历 (按时间倒叙排列)

- 2008.09-2015.06 武汉大学 微生物学 硕博连读 博士
- 2004.09-2008.06 武汉大学 生物学 本科
- 2020.04-至今 新乡医学院 校聘教授
- 2016.2-2020.02 美国 Moffitt cancer center 博士后

## 参加项目 (按时间倒叙排列)

- 国家自然科学基金青年基金, 项目名称: E3泛素连接酶Cdc20调控REST促进卵巢癌增生的分子机制研究, 2021/01-2023/12, 24万元, 在研, 主持
- 美国NIH, A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment, 2016/01-2018/12, 175万元, 结题, 主要参与
- 佛罗里达州乳腺癌基金会 (Florida Breast Cancer Foundation), Energy Restriction-mediated PRC2 Inhibition to Guide Breast Cancer Therapy, 2018/01-2019/01, 50万元, 结题, 主要参与

## 已发表论文（按时间倒叙排列）

---

以第一作者发表的文章：

1. **Tao Han**, Shulong Jiang, Hong Zheng , Qing Yin , Mengyu Xie, Margaret R Little , Xiu Yin, Ming Chen, Su Jung Song, Amer A Beg, Pier Paolo Pandolfi, Lixin Wan. Interplay between c-Src and the APC/C Co-activator Cdh1 Regulates Mammary Tumorigenesis. *Nature Communications* **10**, Article number: 3716 (2019) (中科院一区 IF:11.878)
2. **Tao Han**, Qing Yin, Lixin Wan. Cycling for renewal: Cell cycle machinery maintains prostate cancer stem-like cells. *EBioMedicine*. 42 (2019) 24–25 (中科院一区 IF:6.68)
3. **Tao Han**, Qing Yin, Lixin Wan. AMPK lifts the PRC2-implemented gene repression. *Mol Cell Oncol*. 2018; 5(3): e1441632.
4. **Tao Han**, Yushun Wan, Jun Wang, Peng Zhao, Yue Yuan, Li Wang, Yinglong She, Linbai Ye, and Ying Zhu. Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the interferon-related pathway. *The Journal of immunology*. 2015, 194(6):2757-68. (中科院二区 top 期刊 IF:4.985)
5. 韩涛, 郇金荣, 吴正辉, 李惠平, 叶林柏 艾滋病的基因治疗策略及慢病毒载体. 医学分子生物学杂志, 2007;4(3): 269-271

以参与作者发表的文章：

6. Qing Yin, **Tao Han**, Bin Fang, Guolin Zhang, Chao Zhang, Evan R. Roberts, Victoria Izumi, Mengmeng Zheng, Shulong Jiang , Xiu Yin, Minjung Kim, Jianfeng Cai, Eric B. Haura, John M. Koomen, Keiran S.M. Smalley, Lixin Wan. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. *Nature Communications* **10**, Article number: 1870 (2019) (中科院一区 IF:11.878)
7. ITCH as a potential therapeutic target in human cancers, *Seminars in Cancer Biology*.2020 (中科院一区 IF:9.6)
8. The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations. *Neuro-Oncology Advances*.2020. 2 (1)
9. Lixin Wan, Kexin Xu, Yongkun Wei, Jinfang Zhang, **Tao Han**, Christopher Fry, Zhao Zhang, Yao Vickie Wang, Liyu Huang, Min Yuan, Weiya Xia, Wei-Chao Chang, Wen-Chien Huang, Chien-Liang Liu, Yuan-Ching Chang, Jinsong Liu, Yun Wu, Victor X. Jin, Xiangpeng Dai, Jianfeng Guo, Jia Liu, Shulong Jiang, Jin Li, John M. Asara, Myles Brown, Mien-Chie Hung, and Wenyi Wei. Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. *Molecular Cell*. 2018 ,69, 279–291 (中科院一区 IF:14.248)

10. Yushun Wan, Wei Cao, **Tao Han**, Sheng Ren, Jian Feng, TieLong Chen, Jun Wang, Ruth Broering, Mengji Lu, Ying Zhu. Inducible Rubicon facilitates viral replication by antagonizing interferon production. *Cellular & Molecular Immunology* (2017) 14, 607–620 (中科院二区 **IF:7.551**)
11. Mingzhen Jing, Jun Wang, Shengli Zhu, Fang Ao, Li Wang, **Tao Han**, Xin Yue, Ying Zhu, Linbai Ye, Shi Liu. Development of a more efficient hepatitis B virus by targeting hepatitis B virus preS to dendritic cells. *Vaccine*.2016, 34 (4), 516-522 (中科院三区 **IF:3.285**)
12. Li Wang, Shengli Zhu, Gang Xu, Jian Feng, **Tao Han**, Fanpeng Zhao, Ying-Long She, Shi Liu, Linbai Ye, Ying Zhu. Gene expression and antiviral activity of interleukin-35 in response to Influenza A Virus infection. *The Journal of Biological Chemistry*. 2016,291 (32), 16863-16876 (中科院二区 **IF:4.010**)
13. Jun Wang, Qing Wang, **Tao Han**, Yong-Kui Li, Sheng-Li Zhu, Fang Ao, Ming-Zhen Jing, Li Wang, Jian Feng, Lin-Bai Ye, Ying Zhu. Interleukin-6 receptor mediates expression of interleukin-32 and interleukin-6 in response to influenza A virus infection. *Cellular and molecular immunology*. (2015) 12, 633–644 (中科院二区 **IF:7.551**)
14. Shi Liu, Nanfang Peng, Qian Hao, Mo Zhang, Yi Zhang, Zhangchuan Xia, Gang Xu, Fanpeng Zhao, Qing Wang, **Tao Han**, Ying Zhu. Human hepatitis B virus S and E antigens inhibit major vault protein signaling in interferon induction pathways. *Journal of Hepatology*. 2015 May;62(5):1015-23. (中科院一区 **IF:14.911**)
15. Han X, Ying XL, Zhou SL, **Han T**, Huang H, Jin Q, Yang F, Sun QY, Sun XX. Characterization of the enterovirus 71 P1 polyprotein expressed in *Pichia pastoris* as a candidate vaccine. *Hum Vaccin Immunother*. 2014 Jul 22;10(8). (中科院四区 **IF:2.229**)
16. Peng Zhao, **Tao Han**, Jin-Jing Guo, Sheng-Li Zhu, Jun Wang, Fang Ao, Ming-Zhen Jing, Ying-Long She, Zheng-Hui Wu, Lin-Bai Ye. HCV NS4B induces apoptosis through the mitochondrial death pathway, *Virus Research*.2012;169(1):1-7 (中科院三区 **IF:2.484**)
17. Y Zhang, Y Li, Y Ma, S Liu, Y She, P Zhao, M Jing, **T Han**, C Yan, Z Wu, J Gao, L Ye. Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. *Am J Physiol Gastrointest Liver Physiol*. 301 (2011) G565-573. (中科院三区 **IF:3.293**)
18. She Y, **Han T**, Ye L, Wu Z. Hepatitis C virus NS2/3 protease regulates HCV IRES-dependent translation and NS5B RdRp activity. *Arch Virol*. 2009;154(9):1465-73. (中科院四区 **IF:2.16**)

## 发明专利：

---

名称：一种预防 EV71 基因工程蛋白质疫苗及其制备方法

发明人：韩雪；周世力；应晓玲；**韩涛**；孙宪迅

专利号：ZL201310066245.X

## 主要学术兼职：

---

1, Archives of virology (IF: 2.16) 审稿人

2, Journal of Cellular Physiology (IF: 3.923) 审稿人

3, EBioMedicine (IF: 6.183) 审稿人

## 荣誉称号：

---

2020.03，获得江西省第二批千人计划（青年）称号